Edward Schnitzer, MD
Physical Medicine & Rehabilitation · Mobile, ALNPI 1073514154
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,936 of the $3,732 with a category attached, or 78.7%. 24 manufacturers reported payments, led by Neuronetics, Inc. at 41.3% of the total. Reporting peaked in 2023 at $1,877 and has fallen 72.5% since, to $517 in 2025.
Across 155 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$2K
- Forte Bio-pharma LLC$905
- Collegium Pharmaceutical, Inc.$404
- Indivior Inc.$130
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$122
- Globus Medical$67
- plus $562 from 18 others
What the payments were for
- Travel & lodging$79621%
- Food & beverage$2,93679%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 4 | $1,542 |
| Forte Bio-pharma LLC | 73 | $905 |
| Collegium Pharmaceutical, Inc. | 32 | $404 |
| Indivior Inc. | 7 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $122 |
| Globus Medical | 2 | $67 |
| Atland Pharmaceuticals, LLC | 2 | $61 |
| Zyla Life Sciences, Inc. | 3 | $55 |
| Daiichi Sankyo Inc. | 4 | $52 |
| Virtus Pharmaceuticals LLC | 2 | $50 |
| Boston Scientific | 3 | $47 |
| Valinor Pharma, LLC | 3 | $45 |
| UCB, Inc. | 1 | $44 |
| Galt Pharmaceuticals, LLC | 1 | $42 |
| Tonix Medicines, Inc. | 1 | $31 |
| Biotronik NRO, Inc. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $20 |
| Merck | 1 | $17 |
| Orexo US, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
| Pfizer | 1 | $11 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$1,461
- Prolate$786
- Nalocet$197
How this compares
$3,732 in reported general payments places this provider in the 85th percentile of 104 physical medicine & rehabilitation providers in Alabama.
See all physical medicine & rehabilitation providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlateOxycodone Hcl/Acetaminophen | 76 | $180,426 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,939 | $111,122 |
| Xtampza ErOxycodone Myristate | 121 | $95,015 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 3,841 | $87,715 |
| OxycontinOxycodone Hcl | 70 | $66,052 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 216 | $52,294 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 51 | $34,627 |
| Oxycodone Hcl | 1,133 | $18,392 |
| Morphine Sulfate ErMorphine Sulfate | 471 | $15,827 |
| MovantikNaloxegol Oxalate | 36 | $14,852 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 17 | $13,821 |
| Pregabalin | 649 | $13,480 |
| LinzessLinaclotide | 20 | $11,999 |
| Gabapentin | 1,169 | $11,784 |
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $9,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Forte Bio-pharma LLCProlate | $905 | $180,42676 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $404 | $95,015121 claims |
| Indivior Inc.Suboxone | $130 | $34,62751 claims |
| Orexo US, Inc.Zubsolv | $13 | $13,82117 claims |
| AbbVieLinzess | $11 | $11,99920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 104 physical medicine & rehabilitation providers in Alabama.
Other physical medicine & rehabilitation in Mobile
- Ankit GulatiMobile$4K
- Matthew HasleyMobile$3K
- Charles HallMobile$2K
- Ashley SteffensMobile$1K
- Don McCormickBirmingham$22K
- Bradly GoodmanBirmingham$15K
- Nelson Santos AgostoBirmingham$14K
- John PantuoscoBirmingham$12K
- Ross LumsdenBirmingham$11K
- Michael RosemoreBessemer$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.